Activate Now
 
ProHealth me-cfs Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

May 12th is International ME/CFS, Lyme, and FM Awareness Day!

Are You ‘Activated’? Mast Cell Activation Syndrome and ME/CFS/FM

A Path Of Emotional Growth

What Are You Looking Forward To?

ME/CFS in Children

3 Ways to Support Your Spouse When You're Chronically Ill

Low Dose Naltrexone - An Effective Treatment for ME/CFS?

You Can Change Your Mind

An Eye on "The Mitochondria Man": Robert Naviaux and Chronic Fatigue Syndrome (ME/CFS)

8 Hacks to Slash Medication Costs

 
Print Page
Email Article

Results of Switching Fibromyalgia Patients from Cymbalta to Savella

  [ 5 votes ]   [ Discuss This Article ]
www.ProHealth.com • May 14, 2013


Editor's comment:  There are currently three drugs that have received FDA approval for the treatment of fibromyalgia (brand names: Lyrica, Cymbalta and Savella).  Each one has roughly a 30% success rate for improving FM symptoms.  Therefore, when one medication is not helping a patient, it is not unusual for the treating physician to switch the patient to one of the other approved drugs.  The purpose of this study was to assess the results of switching fibromyalgia patients who were not being helped by duloxotine (Cymbalta) to milnacipran (Savella).  The researchers sought to answer two primary questions: (1) Would patients experience any improvements in pain or other symptoms after switching medications? (2) Can patients be switched from one medication to the other without first tapering down the dosage of the first medication?

Note: You may read the full text of this article free HERE.


Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study

By Lucinda Bateman, et al.

Abstract:

BACKGROUND: The purpose of this study was to evaluate the safety, tolerability, and efficacy of milnacipran following a direct switch from duloxetine in fibromyalgia patients experiencing inadequate clinical response to duloxetine after receiving treatment for 6 weeks or longer.

METHODS: This exploratory study included 107 patients with fibromyalgia who had been treated with duloxetine 60 mg/day for at least 4 weeks prior to enrollment. Following a 2-week open-label period on duloxetine, patients who had visual analog scale pain scores ? 40 and were dissatisfied with current treatment were randomized 4:1 to milnacipran 100 mg/day (n = 86) or placebo (n = 21) for 10 weeks of double-blind treatment. The small placebo group was included solely to blind the study and minimize expectation bias among patients and investigators, and there was no preplanned statistical comparison between treatment groups.

The primary efficacy parameter was the percentage of patients rating themselves as "much improved" or "very much improved" on the Patient Global Impression of Change (PGIC) at the final visit. Other efficacy parameters included changes in one-week recall visual analog scale pain, Fibromyalgia Impact Questionnaire Revised (FIQR), and Multiple Ability Self-Report Questionnaire (MASQ).

RESULTS: Of patients switched to milnacipran, 32.9% were classified as PGIC responders, and they also demonstrated improvement in visual analog scale pain, FIQR total, and MASQ total scores (mean changes from baseline were -12.3, -7.77, and -2.39, respectively).

Nausea and dizziness were the most common treatment-emergent adverse events in patients switched to milnacipran, reported in 21% and 15%, respectively, of patients in this group.

CONCLUSION: Results from this exploratory study suggest that switching from duloxetine to milnacipran may be beneficial in some patients with fibromyalgia who have an inadequate response to duloxetine. Further research investigating the efficacy and safety of switching fibromyalgia therapies is warranted.

Source: Journal of Pain Research, April 26, 2013. By Lucinda Bateman, Robert H Palmer, Joel M Trugman, and Yuhua Lin. Fatigue Consultation Clinic, Salt Lake City, UT.





Post a Comment

Featured Products From the ProHealth Store
Energy NADH™ 12.5mg Mitochondria Ignite™ with NT Factor® B-12 Extreme™

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments



Be the first to comment on this article!

Post a Comment


 
20 Helpful Tips for Cleaning and Organizing When You're Chronically Ill

Featured Products

Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
MitoQ® MitoQ®
Powerful Antioxidant Support to Mitochondria
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Hydroxocobalamin Extreme™ Hydroxocobalamin Extreme™
The B-12 Your Brain Needs for Detox & Sharpness
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium

Natural Remedies

Ubiquinol - A More Advanced Form of the Energy Producing Nutrient CoQ-10 Ubiquinol - A More Advanced Form of the Energy Producing Nutrient CoQ-10
Live Without Anxiety or Stress
How Glutathione Can Save Your Life How Glutathione Can Save Your Life
Cocoa's Polyphenol Riches - All the Health Benefits without the Sugar, Calories or Guilt Cocoa's Polyphenol Riches - All the Health Benefits without the Sugar, Calories or Guilt
Energy Breakthrough - One Fibromyalgia Patient’s Fortuitous Discovery Energy Breakthrough - One Fibromyalgia Patient’s Fortuitous Discovery

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler

· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE AND SAVE 15% NOW*
Be the first to know about new products, special discounts and the latest health news. *New subscribers only

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map